PMID- 34459378
OWN - NLM
STAT- MEDLINE
DCOM- 20220328
LR  - 20220401
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 27
IP  - 43
DP  - 2021
TI  - Perfluorocarbons Therapeutics in Modern Cancer Nanotechnology for Hypoxiainduced 
      Anti-tumor Therapy.
PG  - 4376-4387
LID - 10.2174/1381612827666210830100907 [doi]
AB  - With an estimated failure rate of about 90%, immunotherapies that are intended 
      for the treatment of solid tumors have caused an anomalous rise in the mortality 
      rate over the past decades. It is apparent that resistance towards such therapies 
      primarily occurs due to elevated levels of HIF-1 (Hypoxia-induced factor) in 
      tumor cells, which are caused by disrupted microcirculation and diffusion 
      mechanisms. With the advent of nanotechnology, several innovative advances were 
      brought to the fore; and, one such promising direction is the use of 
      perfluorocarbon nanoparticles in the management of solid tumors. Perfluorocarbon 
      nanoparticles enhance the response of hypoxia-based agents (HBAs) within the 
      tumor cells and have been found to augment the entry of HBAs into the tumor 
      micro-environment. The heightened penetration of HBAs causes chronic hypoxia, 
      thus aiding in the process of cell quiescence. In addition, this technology has 
      also been applied in photodynamic therapy, where oxygen self-enriched 
      photosensitizers loaded perfluorocarbon nanoparticles are employed. The resulting 
      processes initiate a cascade, depleting tumour oxygen and turning it into a 
      reactive oxygen species eventually to destroy the tumour cell. This review 
      elaborates on the multiple applications of nanotechnology based perfluorocarbon 
      formulations that are being currently employed in the treatment of tumour 
      hypoxia.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Satija, Saurabh
AU  - Satija S
AD  - School of Pharmaceutical Sciences, Lovely Professional University, 
      Phagwara-144411, Punjab, India.
FAU - Sharma, Prabal
AU  - Sharma P
AD  - School of Pharmaceutical Sciences, Lovely Professional University, 
      Phagwara-144411, Punjab, India.
FAU - Kaur, Harpreet
AU  - Kaur H
AD  - School of Pharmaceutical Sciences, Lovely Professional University, 
      Phagwara-144411, Punjab, India.
FAU - Dhanjal, Daljeet S
AU  - Dhanjal DS
AD  - School of Bioengineering and Biosciences, Lovely Professional University, 
      Phagwara-144411, Punjab, India.
FAU - Chopra, Reena S
AU  - Chopra RS
AD  - School of Bioengineering and Biosciences, Lovely Professional University, 
      Phagwara-144411, Punjab, India.
FAU - Khurana, Navneet
AU  - Khurana N
AD  - School of Pharmaceutical Sciences, Lovely Professional University, 
      Phagwara-144411, Punjab, India.
FAU - Vyas, Manish
AU  - Vyas M
AD  - School of Pharmaceutical Sciences, Lovely Professional University, 
      Phagwara-144411, Punjab, India.
FAU - Sharma, Neha
AU  - Sharma N
AD  - School of Pharmaceutical Sciences, Lovely Professional University, 
      Phagwara-144411, Punjab, India.
FAU - Tambuwala, Murtaza M
AU  - Tambuwala MM
AD  - School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, 
      County Londonderry, BT52 1SA, Northern Ireland, United Kingdom.
FAU - Bakshi, Hamid A
AU  - Bakshi HA
AD  - School of Pharmacy and Pharmaceutical Sciences, Ulster University, Coleraine, 
      County Londonderry, BT52 1SA, Northern Ireland, United Kingdom.
FAU - Charbe, Nitin B
AU  - Charbe NB
AD  - Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, 1010 West 
      Avenue B, MSC 131, Kingsville, Texas, 78363, United States.
FAU - Zacconi, Flavia C
AU  - Zacconi FC
AD  - Institute for Biological and Medical Engineering, Schools of Engineering, 
      Medicine and Biological Sciences, Pontificia Universidad Catolica de Chile, 
      Santiago, Chile.
FAU - Chellappan, Dinesh K
AU  - Chellappan DK
AD  - Department of Life Sciences, School of Pharmacy, International Medical 
      University, Bukit Jalil 57000, Kuala Lumpur, Malaysia.
FAU - Dua, Kamal
AU  - Dua K
AD  - Discipline of Pharmacy, Graduate School of Health, University of Technology 
      Sydney, Ultimo NSW 2007, Australia.
FAU - Mehta, Meenu
AU  - Mehta M
AD  - School of Pharmaceutical Sciences, Lovely Professional University, 
      Phagwara-144411, Punjab, India.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Fluorocarbons)
RN  - 0 (Photosensitizing Agents)
SB  - IM
MH  - Cell Line, Tumor
MH  - *Fluorocarbons/pharmacology/therapeutic use
MH  - Humans
MH  - *Nanoparticles
MH  - Nanotechnology
MH  - *Neoplasms/pathology
MH  - *Photochemotherapy/methods
MH  - Photosensitizing Agents/pharmacology
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - HBA
OT  - HIF-1
OT  - Tumour hypoxia
OT  - cancer.
OT  - nanotechnology
OT  - perfluorocarbons
EDAT- 2021/08/31 06:00
MHDA- 2022/03/29 06:00
CRDT- 2021/08/30 08:45
PHST- 2021/03/14 00:00 [received]
PHST- 2021/06/28 00:00 [accepted]
PHST- 2021/08/31 06:00 [pubmed]
PHST- 2022/03/29 06:00 [medline]
PHST- 2021/08/30 08:45 [entrez]
AID - CPD-EPUB-117545 [pii]
AID - 10.2174/1381612827666210830100907 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2021;27(43):4376-4387. doi: 10.2174/1381612827666210830100907.